From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway
DOI:
https://doi.org/10.2340/1651-226X.2024.41266Keywords:
real-world data, melanoma patients, tumor characteristics, treatment management, clinical trialsAbstract
Background and purpose: Norway has one of the highest rates of cutaneous melanoma (CM) incidence and mortality globally. Immune checkpoint inhibitor (ICI) therapy for CM was introduced between 2014 and 2017 to improve treatment and patient prognosis, but knowledge about its clinical usage is limited. This study investigates patient’s characteristics and treatment patterns in real-world practice compared to clinical trial results.
Material and methods: All adult (≥18) CM patients treated with ICI therapy in Norway from 2014 to 2021 were included, utilizing high-coverage data from multiple national registries to describe patients’ health, socioeconomic factors, and treatment management, stratified by first ICI therapy. We compared patient and tumour characteristics with findings from five randomized controlled trials (RCTs).
Results: Among 2,083 patients receiving ICI therapy, 975 (47%) received nivolumab as their first treatment in the metastatic setting. Patients on combination therapy were younger and had higher education and income levels compared to those on monotherapy. Overall, real-world patients were older and had a higher incidence of brain metastases than those in RCTs. Approximately, 1 in 5 patients would have been excluded from RCTs due to pre-existing autoimmune diseases. Targeted therapy was the most common secondary systemic treatment after first-line PD-1 inhibitors.
Interpretation: This study details ICI therapy in Norway, highlighting differences between real-world ICI users and clinical trial participants, raising questions about the effectiveness of this treatment for patients not eligible for trials.
Downloads
References
Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2017;18(5):611–22.
https://doi.org/10.1016/S1470-2045(17)30231-0 DOI: https://doi.org/10.1016/S1470-2045(17)30231-0
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
https://doi.org/10.1056/NEJMoa1504030 DOI: https://doi.org/10.1056/NEJMoa1504030
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.
https://doi.org/10.1056/NEJMoa1503093 DOI: https://doi.org/10.1056/NEJMoa1503093
Robsahm TE, Helsing P, Nilssen Y, Vos L, Rizvi SMH, Akslen LA, et al. High mortality due to cutaneous melanoma in Norway: a study of prognostic factors in a nationwide cancer registry. Clin Epidemiol. 2018;10:537–48.
https://doi.org/10.2147/CLEP.S151246 DOI: https://doi.org/10.2147/CLEP.S151246
Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: Implications for adjuvant treatment. J Clin Oncol. 2022;40(32):3741–9.
https://doi.org/10.1200/JCO.22.00202 DOI: https://doi.org/10.1200/JCO.22.00202
Winge-Main A, Robsahm TE, Nyakas M, Festervoll G, Torkilseng E, Thybo S, et al. Long-term outcomes of stage IIB–IV melanoma patients: nationwide data from Norway. Future Oncol. 2023;19(3):205–15.
https://doi.org/10.2217/fon-2022-0969 DOI: https://doi.org/10.2217/fon-2022-0969
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Weber JS, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. DOI: https://doi.org/10.1056/NEJMoa1003466
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–46.
https://doi.org/10.1056/NEJMoa1910836 DOI: https://doi.org/10.1056/NEJMoa1910836
Mahoney KM, Freeman GJ, McDermott DF. The Next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 2015;37(4):764–82.
https://doi.org/10.1016/j.clinthera.2015.02.018 DOI: https://doi.org/10.1016/j.clinthera.2015.02.018
Metoder N. Nye Metoder]. [cited 2023 Sep 15]. Available from: https://www.nyemetoder.no/
Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–26.
https://doi.org/10.1056/NEJMoa1104621 DOI: https://doi.org/10.1056/NEJMoa1104621
Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465–77.
https://doi.org/10.1016/S1470-2045(20)30494-0 DOI: https://doi.org/10.1016/S1470-2045(20)30494-0
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643–54. DOI: https://doi.org/10.1016/S1470-2045(21)00065-6
Helsedirektorate. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne melanomer 2023. [cited 2023 May 10] Available from: https://www.helsedirektoratet.no/retningslinjer/melanomer-handlingsprogram
Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, et al. Ipilimumab in a real-world population: a prospective Phase IV trial with long-term follow-up. Int J Cancer. 2022;150(1):100–11.
https://doi.org/10.1002/ijc.33768 DOI: https://doi.org/10.1002/ijc.33768
da Costa LMM, Crovador CS, de Carvalho CEB, Vazquez VL. Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. BMC Res Notes. 2019;12(1):296.
https://doi.org/10.1186/s13104-019-4336-7 DOI: https://doi.org/10.1186/s13104-019-4336-7
Haque W, Verma V, Butler EB, Teh BS. Racial and socioeconomic disparities in the delivery of immunotherapy for metastatic melanoma in the United States. J Immunother. 2019;42(6):228–35.
https://doi.org/10.1097/CJI.0000000000000264 DOI: https://doi.org/10.1097/CJI.0000000000000264
Donia M, Kimper-Karl ML, Hoyer KL, Bastholt L, Schmidt H, Svane IM. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. Eur J Cancer. 2017;74:89–95.
https://doi.org/10.1016/j.ejca.2016.12.017 DOI: https://doi.org/10.1016/j.ejca.2016.12.017
Donia M, Ellebaek E, Ollegaard TH, Duval L, Aaby JB, Hoejberg L, et al. The real-world impact of modern treatments on the survival of patients with metastatic melanoma. Eur J Cancer. 2019;108:25–32.
https://doi.org/10.1016/j.ejca.2018.12.002 DOI: https://doi.org/10.1016/j.ejca.2018.12.002
Cancer Registry of Norway. Norwegian Institute of Public Health. Cancer in Norway 2023 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway, 2024.
BBrenn HH, Robsahm TE, Dørum LM, Svendsen HL. Nasjonalt kvalitetsregister for melanom bidrar til å styrke kvaliteten på helsehjelpen som gis til melanompasienter. Norsk Epidemiologi. 2023;31(1–2):65-71.
https://doi.org/10.5324/nje.v31i1-2.5614 DOI: https://doi.org/10.5324/nje.v31i1-2.5614
Walters S, Maringe C, Butler J, Brierley JD, Rachet B, Coleman MP. Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership. Int J Cancer. 2013;132(3):676–85.
https://doi.org/10.1002/ijc.27651 DOI: https://doi.org/10.1002/ijc.27651
Enerly E, Holmstrøm L, Skog A, Knudsen KO, Nygård JF, Møller B, et al. INSPIRE: a new opportunity for cancer pharmacoepidemiology research. Norsk Epidemiologi. 2021;29(1–2): 29-33.
https://doi.org/10.5324/nje.v29i1-2.4043 DOI: https://doi.org/10.5324/nje.v29i1-2.4043
Nilssen Y, Strand T-E, Wiik R, Bakken IJ, Yu XQ, O’Connell D, et al. Utilizing national patient-register data to control for comorbidity in prognostic studies. Clin Epidemiol. 2014;2014:395–404.
https://doi.org/10.2147/CLEP.S70742 DOI: https://doi.org/10.2147/CLEP.S70742
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.
https://doi.org/10.1056/NEJMoa1412082 DOI: https://doi.org/10.1056/NEJMoa1412082
Arheden A, Skalenius J, Bjursten S, Stierner U, Ny L, Levin M, et al. Real-world data on PD-1 inhibitor therapy in metastatic melanoma. Acta Oncol. 2019;58(7):962–6.
https://doi.org/10.1080/0284186X.2019.1620966 DOI: https://doi.org/10.1080/0284186X.2019.1620966
Virtanen S, Pihlman H, Silvoniemi M, Vihinen P, Jaakkola P, Mattila KE. Reasons for treatment discontinuation and their effect on outcomes of immunotherapy in Southwest Finland: a retrospective, real-world cohort study. Cancers. 2024;16(4):709.
https://doi.org/10.3390/cancers16040709 DOI: https://doi.org/10.3390/cancers16040709
Fiva JH, Haegeland T, Ronning M, Syse A. Access to treatment and educational inequalities in cancer survival. J Health Econ. 2014;36:98–111.
https://doi.org/10.1016/j.jhealeco.2014.04.001 DOI: https://doi.org/10.1016/j.jhealeco.2014.04.001
Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016;29(6):627–42.
https://doi.org/10.1111/pcmr.12538 DOI: https://doi.org/10.1111/pcmr.12538
Ascierto PA, Kirkwood JM, Grob J-J, Simeone E, Grimaldi AM, Maio M, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10(1):85.
https://doi.org/10.1186/1479-5876-10-85 DOI: https://doi.org/10.1186/1479-5876-10-85
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Denise Reis Costa, Anna K. Winge-Main, Anna Skog, Kaitlyn M. Tsuruda, Trude Eid Robsahm, Bettina Kulle Andreassen
This work is licensed under a Creative Commons Attribution 4.0 International License.
